0001104659-24-097867.txt : 20240906 0001104659-24-097867.hdr.sgml : 20240906 20240906200306 ACCESSION NUMBER: 0001104659-24-097867 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240904 FILED AS OF DATE: 20240906 DATE AS OF CHANGE: 20240906 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dambkowski Carl CENTRAL INDEX KEY: 0001983476 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41740 FILM NUMBER: 241285638 MAIL ADDRESS: STREET 1: 221 CRESCENT ST. STREET 2: BUILDING 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apogee Therapeutics, Inc. CENTRAL INDEX KEY: 0001974640 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 934958665 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 221 CRESCENT ST. STREET 2: BUILDING 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 650-394-5230 MAIL ADDRESS: STREET 1: 221 CRESCENT ST. STREET 2: BUILDING 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Apogee Therapeutics, LLC DATE OF NAME CHANGE: 20230420 4 1 tm2423502-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-09-04 0 0001974640 Apogee Therapeutics, Inc. APGE 0001983476 Dambkowski Carl C/O APOGEE THERAPEUTICS, INC. 221 CRESCENT ST., BLDG. 17, STE. 102B WALTHAM MA 02453 0 1 0 0 Chief Medical Officer 1 Common Stock 2024-09-04 4 S 0 5878 47.49 D 281580 D Common Stock 2024-09-04 4 S 0 787 48.06 D 280793 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.79 to $47.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.80 to $48.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. /s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski 2024-09-06